Author

Geert D’Haens 1

1 Academic Medical Center,Amsterdam,Netherlands

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

Marc Ferrante, William Sandborn, Bal R Bandhari, Geert D’Haens, Brian G. Feagan, Michael Durante, Vipin Arora, Jay Tuttle, April Naegeli

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY

Remo Panaccione, Xavier Hebuterne, James Lindsay, Jianzhong Liu, Hiroshi Nakase, Geert D’Haens, Wangang Xie

Histologic remission and mucosal healing in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

Rish K. Pai, James Canavan, Jay Tuttle, Michael Durante, Vipin Arora, Catherine Milch, Noam Harpaz, Geert D’Haens, Bruce E. Sands, William Sandborn

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Marla C. Dubinsky, William J. Sandborn, Sean Gardiner, Rajiv Mundayat, Irene Modesto, Jerome Paulissen, Severine Vermeire, Paulo Kotze, Chinyu Su, Nervin Lawendy, nicole kulisek, Geert D’Haens, Joana Torres

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese, Brian G. Feagan, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, William Sandborn, Geert D’Haens

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert D’Haens

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert D’Haens, Omoniyi J. Adedokun, Silvio Danese, Severine Vermeire, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Daniel R. Gaya, Laurent Peyrin-Biroulet

REAL WORLD CLINICAL AND ENDOSCOPIC OUTCOMES AFTER ONE YEAR TOFACITINIB TREATMENT IN ULCERATIVE COLITIS

Tessa Straatmijer, Sara van Gennep, Marjolijn Duijvestein, Cyriel Y. Ponsioen, Krisztina Barbara Gecse, Geert D’Haens, Mark Lowenberg

Item 1 - 10 / 11
1
2